RANI vs. GLSI, TARA, HURA, PLX, CABA, THTX, CCCC, ATOS, CRBU, and EXOZ
Should you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), TuHURA Biosciences (HURA), Protalix BioTherapeutics (PLX), Cabaletta Bio (CABA), Theratechnologies (THTX), C4 Therapeutics (CCCC), Atossa Therapeutics (ATOS), Caribou Biosciences (CRBU), and Exozymes (EXOZ). These companies are all part of the "pharmaceutical products" industry.
Rani Therapeutics vs. Its Competitors
Greenwich LifeSciences (NASDAQ:GLSI) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking.
Rani Therapeutics received 26 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 81.40% of users gave Rani Therapeutics an outperform vote while only 47.37% of users gave Greenwich LifeSciences an outperform vote.
Greenwich LifeSciences' return on equity of -185.12% beat Rani Therapeutics' return on equity.
Greenwich LifeSciences has higher earnings, but lower revenue than Rani Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Greenwich LifeSciences and Greenwich LifeSciences both had 1 articles in the media. Greenwich LifeSciences' average media sentiment score of 1.87 beat Rani Therapeutics' score of 0.43 indicating that Greenwich LifeSciences is being referred to more favorably in the media.
4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 50.4% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Greenwich LifeSciences has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.
Greenwich LifeSciences currently has a consensus target price of $39.00, suggesting a potential upside of 304.98%. Rani Therapeutics has a consensus target price of $9.40, suggesting a potential upside of 1,541.35%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Greenwich LifeSciences.
Summary
Rani Therapeutics beats Greenwich LifeSciences on 11 of the 16 factors compared between the two stocks.
Get Rani Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rani Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RANI) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy RANI Stock Free RANI Stock Alerts